Therapeutic approaches for “sick sinus syndrome” rely on electrical pacemakers, which lack hormone responsiveness and bear hazards such as infection and battery failure. These issues may be overcome via “biological pacemakers” derived from pluripotent stem cells (PSCs). Here, we show that forward programming of PSCs with the nodal cell inducer TBX3 plus an additional Myh6-promoter-based antibiotic selection leads to cardiomyocyte aggregates consisting of >80% physiologically and pharmacologically functional pacemaker cells. These induced sinoatrial bodies (iSABs) exhibited highly increased beating rates (300–400 bpm), coming close to those found in mouse hearts, and were able to robustly pace myocardium ex vivo. Our study introduces iSABs as highly pure, functional nodal tissue that is derived from PSCs and may be important for future cell therapies and drug testing in vitro.
TBX3 plus Myh6-promoter antibiotic selection yields pacemaker cells from PSCs
Induced sinoatrial bodies (iSABs) consist of >80% functional pacemaker cells
iSABs showed highly increased beating rates and were able to pace myocardium ex vivo
iSABs represent highly pure functional nodal tissue derived from PSCs
David and colleagues describe how forward programming of PSCs with TBX3 plus additional Myh6-promoter-based antibiotic selection yielded cardiomyocyte aggregates consisting of >80% physiologically and pharmacologically functional pacemaker cells. These induced sinoatrial bodies (iSABs) exhibited highly increased beating rates (300–400 bpm) and were able to pace myocardium ex vivo. Their study introduces iSABs as highly pure functional nodal tissue derived from PSCs.
See how this article has been cited at scite.ai
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.